Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD

伦瓦提尼 医学 顺铂 肝细胞癌 化疗 肿瘤科 内科学 索拉非尼
作者
Masafumi Ikeda,Tatsuya Yamashita,Sadahisa Ogasawara,Masatoshi Kudo,Yoshitaka Inaba,Manabu Morimoto,Kaoru Tsuchiya,Satoshi Shimizu,Yasushi Kojima,Atsushi Hiraoka,Kazuhiro Nouso,Hiroshi Aikata,Kazushi Numata,Tosiya Sato,Takuji Okusaka,Junji Furuse
出处
期刊:Liver cancer [Karger Publishers]
卷期号:13 (2): 193-202 被引量:18
标识
DOI:10.1159/000531820
摘要

<b><i>Introduction:</i></b> Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher antitumor activity is expected for the combination treatment. The aim of this trial was to evaluate the efficacy and safety of lenvatinib in combination with HAIC using cisplatin in patients with advanced HCC. <b><i>Methods:</i></b> In this multicenter, open-labeled, single-arm, phase II trial, patients with advanced HCC categorized as Child-Pugh class A with no prior history of systemic therapy were enrolled. Patients received lenvatinib plus HAIC with cisplatin (lenvatinib: 12 mg once daily for patients ≥60 kg, 8 mg once daily for patients &lt;60 kg; HAIC with cisplatin: 65 mg/m<sup>2</sup>, day 1, every 4–6 weeks, maximum of six cycles). The primary endpoint was the objective response rate (ORR) assessed using modified RECIST by the Independent Review Committee. The secondary endpoints were the ORR assessed using RECIST v1.1, progression-free survival, overall survival, and frequency of adverse events associated with the treatment. <b><i>Results:</i></b> A total of 36 patients were enrolled between September 2018 and March 2020. In the 34 evaluable patients, the ORR assessed by the Independent Review Committee using modified RECIST and RECIST v1.1 were 64.7% (95% confidence interval [CI]: 46.5–80.3%) and 45.7% (95% CI: 28.8–63.4%), respectively. The median progression-free survival and overall survival were 6.3 months (95% CI: 5.1–7.9 months) and 17.2 months (95% CI: 10.9 – not available, months), respectively. The main grade 3–4 adverse events were increased aspartate aminotransferase (34%), leukopenia (22%), increased alanine aminotransferase (19%), and hypertension (11%). <b><i>Conclusion:</i></b> Lenvatinib plus HAIC with cisplatin yielded a favorable ORR and overall survival and was well tolerated in patients with advanced HCC. Further evaluation of this regimen in a phase III trial is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
今年一定离开癫胡完成签到,获得积分10
刚刚
1秒前
研友_VZG7GZ应助11采纳,获得10
1秒前
苹果萧完成签到 ,获得积分10
2秒前
Yxy2021发布了新的文献求助10
2秒前
衡阳完成签到,获得积分10
2秒前
乐闻发布了新的文献求助10
4秒前
alna完成签到,获得积分10
5秒前
微微发布了新的文献求助10
5秒前
阿江shk完成签到,获得积分10
5秒前
wddsf完成签到,获得积分10
5秒前
leadsyew完成签到,获得积分10
5秒前
长安完成签到,获得积分10
5秒前
hyekyo完成签到,获得积分10
6秒前
ren完成签到,获得积分10
6秒前
析渊完成签到,获得积分10
7秒前
11完成签到,获得积分10
8秒前
水濑心源发布了新的文献求助10
8秒前
Zero140发布了新的文献求助10
8秒前
W1ll完成签到,获得积分10
9秒前
9秒前
10秒前
10秒前
Owen应助俭朴从安采纳,获得10
10秒前
10秒前
完美世界应助fireking_sid采纳,获得10
10秒前
啊啊啊完成签到,获得积分10
10秒前
24K纯帅完成签到,获得积分0
10秒前
11秒前
大个应助炸药采纳,获得10
11秒前
干净的问寒完成签到,获得积分20
11秒前
小月完成签到,获得积分10
12秒前
12秒前
一盒火柴完成签到,获得积分10
12秒前
哈h完成签到,获得积分20
12秒前
12秒前
行走人生完成签到,获得积分10
13秒前
鲍勃完成签到,获得积分10
13秒前
共享精神应助iFaceDOG采纳,获得10
13秒前
13秒前
高分求助中
Nickel, Cobalt and Palladium Catalysed Infarction with Ventricular following rich structural diversity 1000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968608
求助须知:如何正确求助?哪些是违规求助? 3513486
关于积分的说明 11168243
捐赠科研通 3248926
什么是DOI,文献DOI怎么找? 1794540
邀请新用户注册赠送积分活动 875188
科研通“疑难数据库(出版商)”最低求助积分说明 804676